IMHO particularly given current price, the entitlement offer is likely to be oversubscribed.Question: Will it be worth putting in for extra's ?Will the extra's be determined proportionally in terms of shareholdings ?
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025